Perelman School of Medicine at the University of Pennsylvania

Control of HSV Infection:  The Action is in the Mucosa

Speaker:  Lawrence Corey MD

Original webcast date:  Apri 19th, 2012

HIV Grand Rounds from the Perelman School of Medicine at the University of Pennsylvania: April 19, 2012
Your name *
Email address *
Degree/Profession *
Country *
How many participants are watching using your internet connection? *
* Required

Jointly Sponsored by Perelman School of Medicine Small JPEG and VE logo 300px

Series Overview:

The Perelman School of Medicine at the University of Pennsylvania and ViralEd are proud to announce the extension of this ground-breaking CME activity. Mirroring academic grand rounds programs, these CME-certified sessions combine traditional academic grand rounds with the innovation and convenience of telemedicine. The "HIV Grand Rounds from the Perelman School of Medicine at the University of Pennsylvania" is delivered live via the Internet every Thursday at noon (12 PM) Eastern Time and is available for on-demand viewing twenty-four hours after the live broadcast.

Presentations cover the most important and current topics in HIV/AIDS and are delivered by the top experts in the field. They are designed to be immediately relevant to practicing HIV clinicians and many are case-based. The final 10 minutes of each one-hour educational activity consists of a live question and answer period, with the presenting faculty member available to answer questions asked by attendees using the webinar interface. These weekly grand rounds are intended to provide clinicians with convenient and easily accessible knowledge and clinical skills they need to provide the best medical care for their HIV-positive patients.

Each session may be broadcast via your Internet connection in your conference room or auditorium for large groups to view, or individually to your personal computer at your convenience. Simply register at for easy access.

Target Audience:

This educational activity is designed for HIV specialists, Infectious Disease specialists, Internal Medicine specialists, Family Practice physicians, Dermatologists, Osteo-specialists, Nephrologists, Hematology/oncologist, Psychiatrists, Public Health professionals, OB/GYN physicians and other clinicians interested and involved in the care of patients with HIV/AIDS.

Commercial Support Acknowledgement:

These activities are supported by educational grants from Gilead Sciences and Janssen Therapeutics.

Learning Objectives for the Series: 

Upon completion of the educational activity, participants should be able to:

  • List the important factors that play a role in ARV therapy success;
  • Explain the role that drug adverse events, drug pharmacokinetics and patient adherence play in achieving ARV success and avoiding morbidity and mortality;
  • Describe the important opportunistic infections and co-morbidities that may affect HIV-positive patients and increase their risk for morbidity and mortality;
  • Discuss the importance of individualizing the care of each HIV-positive patient. 

Course Directors:
Ian Frank, MD
Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania
John Bartlett, MD2
Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, Maryland
Calvin J. Cohen, MD, MS
Research Director,
CRI New England
Clinical Instructor,
Harvard Medical School
Boston, Massachusetts


Lawrence Corey MD
President and Director,
Fred Hutchinson Cancer Research Center
Professor, Medicine and Laboratory Medicine
University of Washington
Seattle, Washington



Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.